Team Metabolic Health

Biocon share price rose in the early trade on after the company’s arm received multiple approval from the US Food and Drug Administration (USFDA). At 09:28am, Biocon was quoting at Rs 360.50, up Rs 1.20, or 0.33 percent, on the BSE.

Pix Credit: Money Control

Biocon Pharma, a wholly owned subsidiary of the company, has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the USFDA. This combination medication is used to treat chronic heart failure in adults and to reduce the risk of death and hospitalization, as well as to treat pediatric patients over the age of one year. The said subsidiary has also received approval of its ANDA for Daptomycin for injection (500mg vial), from the USFDA.

Credit: www.moneycontrol.com